Cargando…

Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study

The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bianchi, Francesco Paolo, Mascipinto, Simona, Stefanizzi, Pasquale, De Nitto, Sara, Germinario, Cinzia, Tafuri, Silvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189124/
https://www.ncbi.nlm.nih.gov/pubmed/33502929
http://dx.doi.org/10.1080/21645515.2020.1871296
_version_ 1783705449732767744
author Bianchi, Francesco Paolo
Mascipinto, Simona
Stefanizzi, Pasquale
De Nitto, Sara
Germinario, Cinzia
Tafuri, Silvio
author_facet Bianchi, Francesco Paolo
Mascipinto, Simona
Stefanizzi, Pasquale
De Nitto, Sara
Germinario, Cinzia
Tafuri, Silvio
author_sort Bianchi, Francesco Paolo
collection PubMed
description The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This study evaluated the proportion of individuals with detectable anti-measles IgG in two groups, those vaccinated with two doses of anti-MMR vaccine and those with a self-reported history of measles infection. Among the 611 students and residents who were tested, 94 (15%) had no detectable protective anti-measles IgG. This proportion was higher among vaccinated individuals (20%; GMT = 92.2) than among those with a self-reported history of measles (6%; GMT = 213.3; p < .0001). After one or two MMR vaccine booster doses, the overall seroconversion rate was 92%. An important proportion of people immunized for measles did not have a protective IgG titer in the years after vaccination, but among those who had a natural infection the rate was three-fold lower. This finding should be considered in the pre-elimination phase, given the resurgence of measles cases among individuals who after being vaccinated lost their circulating IgG after several years, especially if they failed to receive a natural booster.
format Online
Article
Text
id pubmed-8189124
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-81891242021-06-17 Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study Bianchi, Francesco Paolo Mascipinto, Simona Stefanizzi, Pasquale De Nitto, Sara Germinario, Cinzia Tafuri, Silvio Hum Vaccin Immunother Research Paper The persistence of specific IgG after measles infection and after measles vaccination has not been sufficiently investigated. Current evidence suggests that immunity after the disease is life-long, whereas the response after two doses of measles-containing vaccine declines within 10–15 years. This study evaluated the proportion of individuals with detectable anti-measles IgG in two groups, those vaccinated with two doses of anti-MMR vaccine and those with a self-reported history of measles infection. Among the 611 students and residents who were tested, 94 (15%) had no detectable protective anti-measles IgG. This proportion was higher among vaccinated individuals (20%; GMT = 92.2) than among those with a self-reported history of measles (6%; GMT = 213.3; p < .0001). After one or two MMR vaccine booster doses, the overall seroconversion rate was 92%. An important proportion of people immunized for measles did not have a protective IgG titer in the years after vaccination, but among those who had a natural infection the rate was three-fold lower. This finding should be considered in the pre-elimination phase, given the resurgence of measles cases among individuals who after being vaccinated lost their circulating IgG after several years, especially if they failed to receive a natural booster. Taylor & Francis 2021-01-27 /pmc/articles/PMC8189124/ /pubmed/33502929 http://dx.doi.org/10.1080/21645515.2020.1871296 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Research Paper
Bianchi, Francesco Paolo
Mascipinto, Simona
Stefanizzi, Pasquale
De Nitto, Sara
Germinario, Cinzia
Tafuri, Silvio
Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
title Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
title_full Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
title_fullStr Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
title_full_unstemmed Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
title_short Long-term immunogenicity after measles vaccine vs. wild infection: an Italian retrospective cohort study
title_sort long-term immunogenicity after measles vaccine vs. wild infection: an italian retrospective cohort study
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189124/
https://www.ncbi.nlm.nih.gov/pubmed/33502929
http://dx.doi.org/10.1080/21645515.2020.1871296
work_keys_str_mv AT bianchifrancescopaolo longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy
AT mascipintosimona longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy
AT stefanizzipasquale longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy
AT denittosara longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy
AT germinariocinzia longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy
AT tafurisilvio longtermimmunogenicityaftermeaslesvaccinevswildinfectionanitalianretrospectivecohortstudy